Leading vaccine maker seeks market approval
2020-11-26 09:12
A staff member displays a sample of the COVID inactivated vaccine at a vaccine production plant of China National Pharmaceutical Group Co Ltd Sinopharm in Beijing, capital of China, April , . PhotoXinhua    Leading COVID vaccine developer Sinopharm has submitted a market approval application to Chinas top market regulator, Xinhua News Agency quoted the companys Deputy General Manager Shi Shengyi as saying on Wednesday. The Chinese company has two experimental COVID vaccines  both of which are the inactivated type  undergoing Phase  clinical trials overseas. The Xinhua report did not reveal details about the application. Liu Jingzhen, chairman of Sinopharm, said previously that hundreds of thousands of people in China have been injected with either one of the vaccines through emergency authorization, and , of them have traveled abroad after inoculation. No severe adverse effects have been observed among them, and none of those now living overseas has been infected with the virus, he said. Regarding the overseas trials, Liu said nearly , volunteers from  countries have been enrolled in the program, and preliminary results are satisfactory. The companys production capability is expected to exceed  billion doses by the end of next year. China now has five COVID vaccines in Phase  clinical trials in foreign countries, making it a frontrunner in the global race to create a safe, effective vaccine.